A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Summary

Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced). In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable). The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.

Timeline

Start

2023-05-23

Primary completion

2027-05-23

Completion

2027-05-23

Drugs

Indications